Antiemetics: American Society of Clinical Oncology Focused Guideline Update

ASCO open access

 INTRODUCTION

The goal of this update is to provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding the use of netupitant and palonosetron (NEPA). NEPA was approved by the US Food and Drug Administration (FDA) in October 2014 for use in the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of chemotherapy. NEPA is administered orally and consists of a fixed dose of 300 mg of the neurokinin-1 (NK₁) receptor antagonist netupitant combined with 0.50 mg of the 5-hydroxytryptamine type 3 (5-HT₃) receptor antagonist palonosetron.....